The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Castle Biosciences Inc (NASDAQ: CSTL) was $33.57 for the day, up 6.13% from the previous closing price of $31.63. In other words, the price has increased by $6.13 from its previous closing price. On the day, 1.09 million shares were traded. CSTL stock price reached its highest trading level at $34.36 during the session, while it also had its lowest trading level at $31.555.
Ratios:
Our analysis of CSTL’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 30.56. For the most recent quarter (mrq), Quick Ratio is recorded 6.31 and its Current Ratio is at 6.47. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on December 14, 2023, initiated with a Buy rating and assigned the stock a target price of $25.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $54.
On January 07, 2022, Stephens started tracking the stock assigning a Overweight rating and target price of $59.Stephens initiated its Overweight rating on January 07, 2022, with a $59 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 31 ’25 when Oelschlager Kristen M sold 12,678 shares for $25.04 per share. The transaction valued at 317,457 led to the insider holds 27,569 shares of the business.
Derek Maetzold bought 13,390 shares of CSTL for $423,526 on Nov 04 ’25. On Oct 20 ’25, another insider, MAETZOLD DEREK J, who serves as the Pres. & Chief Exec. Officer of the company, sold 1,339 shares for $22.44 each. As a result, the insider received 30,047 and left with 62,988 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CSTL now has a Market Capitalization of 979863296 and an Enterprise Value of 729460288. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.85 while its Price-to-Book (P/B) ratio in mrq is 2.10. Its current Enterprise Value per Revenue stands at 2.123 whereas that against EBITDA is 93.174.
Stock Price History:
The Beta on a monthly basis for CSTL is 1.15, which has changed by -0.050435305 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, CSTL has reached a high of $35.84, while it has fallen to a 52-week low of $14.59. The 50-Day Moving Average of the stock is 42.00%, while the 200-Day Moving Average is calculated to be 58.82%.
Shares Statistics:
CSTL traded an average of 472.59K shares per day over the past three months and 447230 shares per day over the past ten days. A total of 29.16M shares are outstanding, with a floating share count of 28.35M. Insiders hold about 2.86% of the company’s shares, while institutions hold 94.54% stake in the company. Shares short for CSTL as of 1760486400 were 1608069 with a Short Ratio of 3.40, compared to 1757894400 on 1795589. Therefore, it implies a Short% of Shares Outstanding of 1608069 and a Short% of Float of 6.35.
Earnings Estimates
Castle Biosciences Inc (CSTL) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.49 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$0.23 and -$1.08 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$1.53, with 3.0 analysts recommending between -$1.42 and -$1.62.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $79.07M to a low estimate of $70.5M. As of. The current estimate, Castle Biosciences Inc’s year-ago sales were $86.31MFor the next quarter, 7 analysts are estimating revenue of $74.34M. There is a high estimate of $78.2M for the next quarter, whereas the lowest estimate is $69.3M.
A total of 7 analysts have provided revenue estimates for CSTL’s current fiscal year. The highest revenue estimate was $333.8M, while the lowest revenue estimate was $316M, resulting in an average revenue estimate of $330.55M. In the same quarter a year ago, actual revenue was $332.07MBased on 7 analysts’ estimates, the company’s revenue will be $326.91M in the next fiscal year. The high estimate is $337.51M and the low estimate is $318M.
